Association of CTXN3-SLC12A2 polymorphisms and schizophrenia in a Thai population
- Benjaporn Panichareon†1,
- Kazuhiro Nakayama†2,
- Sadahiko Iwamoto2,
- Wanpen Thurakitwannakarn3 and
- Wasana Sukhumsirichart1Email author
© Panichareon et al.; licensee BioMed Central Ltd. 2012
Received: 26 September 2011
Accepted: 29 May 2012
Published: 29 May 2012
A genome-wide association study (GWAS) combined with brain imaging as a quantitative trait analysis revealed that the SNPs near CTXN3-SLC12A2 region were related to forebrain development and stress response which involved in schizophrenia. In the present study, the SNPs in this region were analyzed for association with schizophrenia in a Thai population.
A total of 115 schizophrenia and 173 unrelated normal controls with mean age of 37.87 ± 11.8 and 42.81 ± 6.0 years, respectively, were included in this study. Genotyping was performed using polymerase chain reaction and high-resolution melting (HRM) analysis. The difference in genotype distribution between patient and control was assessed by Chi-square test of the SPSS software.
We found a significant association between the GWAS-discovered SNP, rs245178, with the risk of schizophrenia in the Thai population [P = 0.006, odds ratio for the minor G allele: 0.62(0.46–0.83)]. Additionally, another potential SNP, rs698172, which was in moderate linkage disequilibrium with rs245178, also showed strong association with schizophrenia [P = 0.003, odds ratio for minor T allele: 0.61(0.46–0.82)]. This association remained significant at 5% level after the Bonferroni correction for multiple testing.
This study shows that two SNPs in intergenic of the CTXN3 and SLC12A2 genes, rs245178 and rs698172, are associated with risk of schizophrenia in Thai population. Further study is required for clarification the role of genetic variation around these SNPs in expression pattern of the CTXN3 and SLC12A2 genes, which may be involved in schizophrenia pathogenesis.
Schizophrenia is characterized by abnormalities in perception, thought, cognition, and expression of reality. It is clinically described by positive and negative symptoms . Positive symptoms are psychotic behaviors that are present in schizophrenia but absent in healthy individuals, include hallucinations, delusions, and thought disorder. Negative symptoms are factors that absent in schizophrenia patients but are present in healthy persons . Schizophrenia is one of the most common psychiatric disorders and its prevalence is 1% of the worldwide population . Twin and family studies suggest that genetic factors play a major role in schizophrenia [4, 5].
A variety of genetic studies reported several chromosomal regions associated with schizophrenia and related phenotypes. A quantitative trait locus for schizophrenia was mapped to a chromosome 5 region in Americans of European ancestry . A meta-analysis of European ethnicity showed that the 5q23.2-q34 region was significantly linked with schizophrenia .
A genome wide association study (GWAS) in combination with the data from brain imaging of dorsolateral prefrontal cortex (DLPFC) as quantitative trait (QT) analysis revealed 6 genes/regions that involved in neurodevelopment and response to stress. The first three genes including ROBO1-ROBO2 TNIK, and CTXN3-SLC12A2 were identified by having 2 single-nucleotide polymorphisms (SNPs) each significant at P < 10−6 for the interaction between the imaging QT and the diagnosis. The other three genes including POU3F2 TRAF, and GPC1 had a significant SNP at <10−6. Because the GWAS was a screening method over the whole genome to identify the SNPs related to risk for schizophrenia and the subject of previous study mostly Caucasian ethnic group . Moreover, there is no association study of those genes and risk of schizophrenia in other ethnic groups rather than European ancestry. A replication study with Asian ethnic groups would help to reinforce the signals obtained in a European GWAS. Furthermore, the testing of a population showing different linkage disequilibrium (LD) structures may assist in identifying the true causative variant in the genomic region of interest.
In Thailand, the prevalence of schizophrenia is comparable with the worldwide value (approximately 1%). Genetic variations associated with risks of schizophrenia have been investigated in opioid-binding protein/cell adhesion molecule (OPCML) gene  using GWAS-discovered SNPs of Europeans ancestry . There was strong association between an intronic SNP of the OPCML gene (rs1784519) and the risk of schizophrenia in a Thai population P = 0.00036, odds ratio for the minor A allele: 2.11(1.57–2.84)] .
This study aims to investigate the association between SNPs in CTXN3-SLC12A2 region with the risk of schizophrenia in the Thai population. The CTXN3 gene is located on 5q23 encode CTXN3 (cortexin 3), a brain specific integral membrane protein highly enriched in cortex. It is expressed in fetal brain and increases in density perinatally. The gene consists of 3 exons and spans an approximate 9.6 kb region. It has 2 alternative transcript variants expressed in the brain and kidneys, and encodes an 81-amino acids protein . This gene is highly conserved in various species, suggesting that this gene plays important roles in brain and kidney function. The gene, SLC12A2 (solute carrier family 12, member 2), found in the same region as CTXN3, encodes a sodium-potassium-chloride (Na-K-Cl) cotransporter protein which is expressed in various human tissues, including the brain . SLC12A2 is involved in the regulation of GABA neurotransmission. Both CTXN3 and SLC12A2 are indicated to play a role in normal brain function, in addition, the CTXN3-SLC12A2 region is considered as the second most important region linked to schizophrenia in the meta-analysis [7, 8], therefore, they may be involved in schizophrenia pathogenesis. This study, the SNPs in the intergenic of CTXN3-SLC12A2 region, 3′-UTR and intronic of CTXN3 gene were analyze for their association with schizophrenia.
A total number of subjects consisted of 115 schizophrenia patients (61 males and 54 females) with a mean age of 37.87 ± 11.8 years and 173 unrelated healthy controls (110 males and 63 females) with a mean age of 42.81 ± 6.0 years. The patients were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria. The healthy controls were also psychiatrically screened to confirm that they did not suffer from a psychiatric disorder. All patients and healthy controls gave informed consent for participation in this study, which was approved by the ethical committee at the Faculty of Medicine, Chiang Mai University and Faculty of Medicine, Srinakharinwirot University.
Genomic DNAs of patient and control were extracted from whole blood (5 ml) using Flexigene DNA kit (Qiagen, German). Genotyping was performed by using polymerase chain reaction (PCR) and followed by high-resolution melting analysis (HRM). PCR primers were designed using LightScanner Primer Design software (Idaho Technology, Salt Lake City, UT, USA) and the primer sequences were included in supplement table (available online). The PCR was carried out using TaKaRa Ex Taq Hot Start Version (TaKaRa, Tokyo, Japan) with LCGreen + (Idaho Technology). The high-resolution melting analysis was performed using a LightScanner (Idaho Technology, USA). Sequences of primers are provided in the Additional file 1.
The linkage disequilibrium (LD) status of the GWAS-discovered marker SNPs; rs245178, rs245201 , and nearby SNPs; rs1421746, rs711360, rs698171, rs698172, rs245314, rs245311, rs245310, rs9285907, rs151849, rs6874357, rs245199, rs245195, rs245192, rs245191, rs1579284, rs181746, rs245186, rs6864687, rs151879, rs245179, rs245181, and rs245183, were determined using 47 randomly selected schizophrenia patients and healthy controls. LD analyses were performed using Haploview software . SNPs with a marked deviation from Hardy-Weinberg equilibrium (P < 0.01) were excluded from further analysis. The association analysis was assessed by using Pearson’s Chi-square test implemented in SPSS program version 11.5 for Window. We assessed 3 genotype models (additive, dominant, and recessive) in the association analysis. The significance level of the association test was set at 5% and moreover, we also applied the Bonferroni correction for the numbers of SNPs tested. For the SNPs showing significant association, mode of inheritance was inferred by using the method proposed Zintzaras and Santos . The generalized odds ratio of genotypes  and odds ratio of the minor allele of each SNP were calculated. For the allelic test, we evaluated statistical power by using the G*Power 3 . Odds ratios that ensured 80% power (P < 0.05) were estimated as 2.00(0.37), 1.74(0.51), 1.65(0.57), 1.62(0.60), and 1.62(0.61), for alleles with frequencies in the controls of 0.1, 0.2, 0.3, 0.4 and 0.5, respectively. We also estimated sex and age adjusted-odds ratio of the SNP genotypes with the aid of multiple logistic regression analysis. Haplotypes of the SNPs were reconstructed by using PHASE2.0 . Differences in haplotype frequencies between the patients and the controls were assessed by using χ2 test.
Association study of SNPs and schizophrenia
Results of the association analyses
Type of SNP
Allelic OR3 Generalized OR
Linkage disequilibrium analysis
Haplotype 2 versus Haplotype 3
In the present study, a total of four SNPs in CTXN3-SLC12A2 region—rs245178, rs698172, rs1421746, and rs698171 were shown to be significantly associated with a risk of schizophrenia in a Thai population that is consistent with the previous GWAS report . Another GWAS-discovered SNP, rs245201, showed a marginal association with schizophrenia (P = 0.052, under the dominant model). In a population of European ancestry (HapMap CEU panel), rs245201 was in absolute LD with rs698172, but this was not the case in our Thai population (r 2 = 0.5). The differences in LD structure would explain the apparent contradiction between these studies. Furthermore, the rs698172, which was separated by 45.5 kb from the rs245178, showed the strongest association with risk of schizophrenia in the Thai group. The minor T allele of rs698172 was shown to reduce the risk of schizophrenia. The haplotype-based association analysis revealed that the frequency of haplotypes of the rs698172 T and rs245178 G alleles was significantly lower in patients (P = 0.005), and the odds ratio was smaller than those of rs698172 and rs245178. Further verification is required to determine whether this haplotype effect is the actual influences susceptibility to schizophrenia. The associations detected for the rs245178 and rs698172 were considered to simply reflect LD of these two SNPs. The rs245178 and rs698172 were located in the intergenic region between CTXN3 and SLC12A2 genes, and it is still unclear whether functional elements affecting gene functions exist in this region.
CTXN3 protein is a brain-specific integral membrane protein, highly enriched within the cortex . It shows 43% homology with cortexin (CTXN 1), which is highly enriched in the cerebral cortex and is probably an integral membrane protein playing a role in the developing and adult cerebral cortex . It is expected that CTXN3 is also a member of the integral membrane proteins and is relevant to the development and function of the cerebral cortex. Another candidate gene in this region, SLC12A2, was expressed in various human tissues, including brain . SLC12A2 was highly expressed in developing cortical neurons and promotes the accumulation of chloride ion (Cl-) in neurons . Moreover, SLC12A2 protein facilitates seizure in the developing brain . The significant associations between SNPs and risk of schizophrenia suggest potential roles of these two genes in the pathogenesis of schizophrenia.
The present study showed that two SNPs in the CTXN3-SLC12A2 region, rs245178, and rs698172 are associated with risk of schizophrenia in Thai population. These SNPs were located in intergenic region with unknown function. Further study, it would be of interest to identify genetic variation around these SNPs affecting the expression pattern of the CTXN3 and SLC12A2 genes and test the association with risk for schizophrenia.
This study was supported by the Royal Golden Jubilee Ph.D. Program of the Thailand Research Fund (PHD/0213/2551); Srinakharinwirot University (149/2550, 218/2552); KAKENHI 21687021. This study was also subsidized by JKA through its promotion funds from KEIRIN RACE. The study sponsors played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or the decision to submit for the paper.
- Andreasen NC, Flaum M: Schizophrenia: the characteristic symptoms. Schizophr Bull. 1991, 17: 27-49.View ArticlePubMedGoogle Scholar
- Tandon R, Nasrallah HA, Keshavan MS: Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res. 2009, 110: 1-23. 10.1016/j.schres.2009.03.005.View ArticlePubMedGoogle Scholar
- Cardno AG, Marshall EJ, Coid B, Macdonald AM, Ribchester TR, Davies NJ, Venturi P, Jones LA, Lewis SW, Sham PC: Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry. 1999, 56: 162-168. 10.1001/archpsyc.56.2.162.View ArticlePubMedGoogle Scholar
- Dworkin RH, Lenzenweger MF: Symptoms and the genetics of schizophrenia: implications for diagnosis. Am J Psychiatry. 1984, 141: 1541-1546.View ArticlePubMedGoogle Scholar
- Kendler KS, Diehl SR: The genetics of schizophrenia: a current, genetic-epidemiologic perspective. Schizophr Bull. 1993, 19: 261-285.View ArticlePubMedGoogle Scholar
- Almasy L, Gur RC, Haack K, Cole SA, Calkins ME, Peralta JM, Hare E, Prasad K, Pogue-Geile MF, Nimgaonkar V, Gur RE: A genome screen for quantitative trait loci influencing schizophrenia and neurocognitive phenotypes. Am J Psychiatry. 2008, 165: 1185-1192. 10.1176/appi.ajp.2008.07121869.PubMed CentralView ArticlePubMedGoogle Scholar
- Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, Williams NM, Schwab SG, Pulver AE, Faraone SV: Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet. 2003, 73: 34-48. 10.1086/376549.PubMed CentralView ArticlePubMedGoogle Scholar
- Potkin SG, Turner JA, Guffanti G, Lakatos A, Fallon JH, Nguyen DD, Mathalon D, Ford J, Lauriello J, Macciardi F: A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Schizophr Bull. 2009, 35: 96-108. 10.1093/schbul/sbn155.PubMed CentralView ArticlePubMedGoogle Scholar
- Panichareon B, Nakayama K, Thurakitwannakarn W, Iwamoto S, Sukhumsirichart W: OPCML Gene as a Schizophrenia Susceptibility Locus in Thai Population. J Mol Neurosci. 2012, 46: 373-377. 10.1007/s12031-011-9595-2.View ArticlePubMedGoogle Scholar
- O’Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V: Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet. 2008, 40: 1053-1055. 10.1038/ng.201.View ArticlePubMedGoogle Scholar
- Wang HT, Chang JW, Guo Z, Li BG: In silico-initiated cloning and molecular characterization of cortexin 3, a novel human gene specifically expressed in the kidney and brain, and well conserved in vertebrates. Int J Mol Med. 2007, 20: 501-510.PubMedGoogle Scholar
- Payne JA, Xu JC, Haas M, Lytle CY, Ward D, Forbush B: Primary structure, functional expression, and chromosomal localization of the bumetanide-sensitive Na-K-Cl cotransporter in human colon. J Biol Chem. 1995, 270: 17977-17985. 10.1074/jbc.270.30.17977.View ArticlePubMedGoogle Scholar
- Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21: 263-265. 10.1093/bioinformatics/bth457.View ArticlePubMedGoogle Scholar
- Zintzaras E, Santos M: Estimating the mode of inheritance in genetic association studies of qualitative traits based on the degree of dominance index. BMC Med Res Methodol. 2011, 11: 171-182. 10.1186/1471-2288-11-171.PubMed CentralView ArticlePubMedGoogle Scholar
- Zintzaras E: The Generalized Odds Ratio as a Measure of Genetic Risk Effect in the Analysis and Meta-Analysis of Association Study. Stat App Genet Mol Biol. 2010, 9: Article 21-Google Scholar
- Faul F, Erdfelder E, Lang AG, Buchner A: G*3 Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007, 39: 175-191. 10.3758/BF03193146.View ArticlePubMedGoogle Scholar
- Stephens M, Donnelly P: A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003, 73: 1162-1169. 10.1086/379378.PubMed CentralView ArticlePubMedGoogle Scholar
- Coulter PM, Bautista EA, Margulies JE, Watson JB: Identification of cortexin: a novel, neuron-specific, 82-residue membrane protein enriched in rodent cerebral cortex. J Neurochem. 1993, 61: 756-759.View ArticlePubMedGoogle Scholar
- Dzhala VI, Talos DM, Sdrulla DA, Brumback AC, Mathews GC, Benke TA, Delpire E, Jensen FE, Staley KJ: NKCC1 transporter facilitates seizures in the developing brain. Nat Med. 2005, 11: 1205-1213. 10.1038/nm1301.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.